Cargando…

Long-term health status as measured by EQ-5D among patients with metastatic breast cancer: comparison of first-line oral S-1 and taxane therapies in the randomized phase III SELECT BC trial

PURPOSE: The goal of chemotherapy for metastatic breast cancer (MBC) is to prolong survival and maintain health-related quality of life. This study aimed to evaluate long-term health status of patients with MBC who participated in the phase III randomized SELECT BC trial. METHODS: In the SELECT BC t...

Descripción completa

Detalles Bibliográficos
Autores principales:	Shiroiwa, T., Fukuda, T., Shimozuma, K., Mouri, M., Hagiwara, Y., Doihara, H., Akabane, H., Kashiwaba, M., Watanabe, T., Ohashi, Y., Mukai, H.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer International Publishing 2016
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5288429/ https://www.ncbi.nlm.nih.gov/pubmed/27517267 http://dx.doi.org/10.1007/s11136-016-1388-1

Ejemplares similares

Cost-effectiveness analysis of the introduction of S-1 therapy for first-line metastatic breast cancer treatment in Japan: results from the randomized phase III SELECT BC trial
por: Shiroiwa, Takeru, et al.
Publicado: (2017)

Impact of Adverse Events on Health Utility and Health-Related Quality of Life in Patients Receiving First-Line Chemotherapy for Metastatic Breast Cancer: Results from the SELECT BC Study
por: Hagiwara, Yasuhiro, et al.
Publicado: (2017)

Psychometric properties of the Japanese version of the EQ-5D-Y by self-report and proxy-report: reliability and construct validity
por: Shiroiwa, T., et al.
Publicado: (2019)

Japanese population norms for preference-based measures: EQ-5D-3L, EQ-5D-5L, and SF-6D
por: Shiroiwa, Takeru, et al.
Publicado: (2015)

Mapping EORTC QLQ-C30 and FACT-G onto EQ-5D-5L index for patients with cancer
por: Hagiwara, Yasuhiro, et al.
Publicado: (2020)

Impacts of the preceding cancer-specific health-related quality of life instruments on the responses to the subsequent EQ-5D-5L
por: Izumi, Shoki, et al.
Publicado: (2023)

Cost-effectiveness analysis of trastuzumab to treat HER2-positive advanced gastric cancer based on the randomised ToGA trial
por: Shiroiwa, T, et al.
Publicado: (2011)

EQ-5D-Y Population Norms for Japanese Children and Adolescents
por: Shiroiwa, Takeru, et al.
Publicado: (2021)

Minimal important differences of EORTC QLQ-C30 for metastatic breast cancer patients: Results from a randomized clinical trial
por: Kawahara, Takuya, et al.
Publicado: (2022)

Valuation Survey of EQ-5D-Y Based on the International Common Protocol: Development of a Value Set in Japan
por: Shiroiwa, Takeru, et al.
Publicado: (2021)

Taxanes for the Treatment of Metastatic Breast Cancer
por: Gradishar, W.J.
Publicado: (2012)

Salvage chemotherapy with irinotecan, 5-fluorouracil and leucovorin for taxane- and cisplatin-refractory, metastatic gastric cancer
por: Kim, S T, et al.
Publicado: (2005)

Cost-effectiveness analysis of XELOX for metastatic colorectal cancer based on the NO16966 and NO16967 trials
por: Shiroiwa, T, et al.
Publicado: (2009)

Cost-Effectiveness of Trastuzumab With or Without Chemotherapy as Adjuvant Therapy in HER2-Positive Elderly Breast Cancer Patients: A Randomized, Open-Label Clinical Trial, the RESPECT Trial
por: Takumoto, Yuki, et al.
Publicado: (2022)

Optimal use of taxanes in metastatic breast cancer
por: King, K.M., et al.
Publicado: (2009)

Taxanes in the elderly patient with metastatic breast cancer
por: Yardley, Denise A
Publicado: (2015)

Patterns and Predictors of First-Line Taxane Use in Patients with Metastatic Triple-Negative Breast Cancer in US Clinical Practice
por: O’Shaughnessy, Joyce, et al.
Publicado: (2021)

P-gp and taxanes
por: Hendrikx, Jeroen J.M.A., et al.
Publicado: (2014)

Class III β-tubulin is a predictive marker for taxane-based chemotherapy in recurrent and metastatic gastric cancer
por: Hwang, Jun-Eul, et al.
Publicado: (2013)

Taxanes in the elderly patient with metastatic breast cancer [Corrigendum]
Publicado: (2019)

Gemcitabine and taxanes in metastatic breast cancer: a systematic review
por: Gudena, Vinay, et al.
Publicado: (2008)

Overview of neuropathy associated with taxanes for the treatment of metastatic breast cancer
por: Rivera, Edgardo, et al.
Publicado: (2015)

Role of HER3 expression and PTEN loss in patients with HER2-overexpressing metastatic breast cancer (MBC) who received taxane plus trastuzumab treatment
por: Park, Y H, et al.
Publicado: (2014)

Economic Evaluation of First-Line Pertuzumab Therapy in Patients with HER2-Positive Metastatic Breast Cancer in Japan
por: Moriwaki, Kensuke, et al.
Publicado: (2021)

Additive and supra-additive cytotoxicity of cisplatin-taxane combinations in ovarian carcinoma cell lines
por: Engblom, P, et al.
Publicado: (1999)

Impact of taxanes on androgen receptor signaling
por: Bai, Shanshan, et al.
Publicado: (2019)

Adjuvant therapy of endometrial cancer: “taxane or not taxane, this is the question”
por: Lorusso, Vito, et al.
Publicado: (2019)

Upfront Taxane Could Be Superior to Pegylated Liposomal Doxorubicin (PLD): A Retrospective Real-World Analysis of Treatment Sequence Taxane–PLD versus PLD–Taxane in Patients with Metastatic Breast Cancer
por: Wallrabenstein, Till, et al.
Publicado: (2023)

A systematic review of taxane-containing regimens for metastatic breast cancer
por: Ghersi, D, et al.
Publicado: (2005)

A systemic review of taxanes and their side effects in metastatic breast cancer
por: Lai, Jiun-I., et al.
Publicado: (2022)

Oral Care Evaluation to Prevent Oral Mucositis in Estrogen Receptor‐Positive Metastatic Breast Cancer Patients Treated with Everolimus (Oral Care‐BC): A Randomized Controlled Phase III Trial
por: Niikura, Naoki, et al.
Publicado: (2019)

Capecitabine and Vinorelbine in Patients with Metastatic Breast Cancer Previously Treated with Anthracycline and Taxane
por: Ahn, Jin-Hee, et al.
Publicado: (2004)

Evolving Approaches to Metastatic Breast Cancer Patients Pre-treated with Anthracycline and Taxane
por: Saji, Shigehira
Publicado: (2013)

Survival analysis of bevacizumab plus taxane treatment in luminal metastatic breast cancer
por: Murillo, Serafin Morales, et al.
Publicado: (2021)

Efficacy of taxanes rechallenge in first-line treatment of early metastatic relapse of patients with HER2-negative breast cancer previously treated with a (neo)adjuvant taxanes regimen: A multicentre retrospective observational study
por: Vasseur, Antoine, et al.
Publicado: (2022)

Real-world treatment in patients with HER2+ metastatic breast cancer: Treatment decisions in HER2+ mBC
por: Colomer, R., et al.
Publicado: (2017)

Mechanisms of Taxane Resistance
por: Maloney, Sara M., et al.
Publicado: (2020)

Ixabepilone: a new treatment option for the management of taxane-resistant metastatic breast cancer
por: Cobham, Marta Vallee, et al.
Publicado: (2009)

Erratum to: Evolving Approaches to Metastatic Breast Cancer Patients Pre-treated with Anthracycline and Taxane
por: Saji, Shigehira
Publicado: (2013)

Identification and cost of adverse events in metastatic breast cancer in taxane and capecitabine based regimens
por: Hansen, Ryan N, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_7vvquikt41g11o7na4fbf696pa